FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 06826 | 說明 | H 股 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | 事件 | ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06826 | H 股 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 ...

2025年4月26日， 昊海生物发布了2024年年报。 # 财报数据 2024年公司实现营业 收入26.98亿元 ，同比 增长1.64% 。归属于母公司股东的净利润为4.20亿元，同比增 长1.04%。整体毛利率为69.88%，同比下降0.63个百分点。 费用变动 现金流 正式报名：首届全球心血管大会 | 赠送纸质白皮书 合作伙伴征集：2025全球手术机器人大会 昊海生物科技（股票代码：688366.SH / 06826.HK）成立于2007年1月24日，是一家专注于生物医用材料 研发、生产和销售的高科技生物医药企业。公司总部位于上海，注册资金1.2亿元人民币，主要从事生物材 料、生物制剂、基因工程药品的研发、生产和销售。 昊海生物科技的主营业务涵盖以下领域： 医疗美容与创面护理产品 公司是 国内第一 大手术防粘连剂生产商，2023年市场份额为28.82%，连续十七年稳居市场首位。 玻尿酸产品 ：公司是国内知名玻尿酸生产商之一，自主研发掌握了单相交联、低温二次交联、线性无颗 粒化交联以及有机交联等交联工艺。第一代产品"海薇"、第二代产品"姣兰"和第三代产品"海魅"已获得 市场广泛认可。 表皮修复基因工程制剂 ...

Core Insights - The medical aesthetics industry is experiencing significant revenue declines among major players, indicating a painful transformation phase for traditional companies [1][2][5] - Huaxi Biological, Aimeike, and Haohai Biological show varying degrees of revenue decline, highlighting differences in business structure and strategic deployment [1][2] - The industry is facing fundamental changes, raising concerns about which companies may fall behind in this transformation [1][8] Company Performance - Huaxi Biological reported a 20.77% year-on-year revenue decline in Q1 2025, with revenue shrinking to 1.078 billion yuan [1] - Aimeike's revenue decreased by 17.90% to 663 million yuan, while Haohai Biological's revenue fell by 4.25% to 619 million yuan [1] - Huaxi Biological's net profit plummeted from 961 million yuan in 2022 to 174 million yuan in 2024, with a further 58.13% decline in Q1 2025 [2][4] Strategic Adjustments - Huaxi Biological is undergoing a significant management overhaul, with leadership changes aimed at addressing operational challenges and improving performance [3][4] - The company is focusing on new fields such as glycoscience and cell biology, which has led to increased management costs [2][3] - Aimeike is shifting its strategy to accelerate product updates and pursue acquisitions in new areas like botulinum toxin and semaglutide [5][6] Market Dynamics - The medical aesthetics market is witnessing intense competition, particularly in the hyaluronic acid segment, raising concerns about whether the market has peaked [8][9] - New materials like hydroxyapatite and recombinant collagen are emerging as potential competitors to hyaluronic acid, indicating a shift in market dynamics [8][9] - Regulatory challenges and lengthy approval processes for medical products are significant barriers to industry growth, impacting companies' ability to innovate [9][10] Future Outlook - Huaxi Biological's turnaround efforts may take time to yield results, especially given its high marketing expenditures [10] - Aimeike's success will depend on the speed of product approvals and market acceptance of its diversified product strategy [6][10] - Haohai Biological is exploring new materials to drive growth, but its performance is still affected by pricing pressures from centralized procurement policies [7][10]

Financial Performance - The company reported total revenue of 619 million yuan for Q1 2025, a decrease of 4.25% year-on-year [1] - The net profit attributable to shareholders was 90.31 million yuan, down 7.41% compared to the same period last year [1] - The gross margin was 69.52%, an increase of 0.44% year-on-year, while the net profit margin decreased to 13.55%, down 5.36% [1] - Total expenses (selling, administrative, and financial) amounted to 272 million yuan, accounting for 43.96% of revenue, an increase of 5.94% year-on-year [1] - Earnings per share (EPS) was 0.39 yuan, a decrease of 7.14% year-on-year [1] Accounts Receivable and Cash Flow - Accounts receivable represented 77.11% of the latest annual net profit, indicating a significant amount of outstanding payments [1] - Operating cash flow per share was 0.37 yuan, down 18.22% year-on-year [1] Business Model and Market Position - The company's return on invested capital (ROIC) was 5.01%, indicating average capital returns [3] - The net profit margin for the previous year was 13.95%, suggesting high added value for products or services [3] - The company relies heavily on marketing-driven performance, necessitating further investigation into the underlying drivers [3] Future Expectations - Analysts expect the company's performance in 2025 to reach 505 million yuan, with an average EPS forecast of 2.17 yuan [4] Fund Holdings - The largest fund holding the company’s shares is Tianhong Pension 2035 Three-Year (FOF) A, with 12,400 shares newly entered into the top ten holdings [5] - The fund's current scale is 120 million yuan, with a net value of 1.0282 as of April 23, showing a 0.12% increase from the previous trading day [5] Product Performance - The company anticipates a 65% year-on-year increase in hyaluronic acid product sales in 2024, despite a slowdown in growth due to market conditions [7]

環境，社會 與管治報告 2024 | 目錄 | | | | --- | --- | --- | | | 關於本報告 | 2 | | | 關於本公司 | 4 | | | 年度主要榮譽及績效亮點 | 5 | | | ESG 管理 | | | | ESG 治理架構 | 8 | | 01 | 董事會聲明 | 8 | | | 利益相關方溝通 | 9 | | | 雙重重要性評估 | 10 | | | 合規運營 | | | | 風險管理與內部控制 | 13 | | 02 | 商業道德 信息安全與隱私保護 | 14 16 | | | 科技倫理 | 17 | | | 產品與創新 | | | | 研發創新 | 19 | | 03 | 知識產權保護 | 24 | | | 供應鏈安全 | 25 | | | 產品安全與質量 | 27 | | | 負責任營銷 | 31 | | | 環境保護 | | | | 應對氣候變化 | | | 04 | 環境管理體系 | 34 39 | | | 排污管理 | 39 | | | 資源管理與循環經濟 | 43 | | | 員工發展 | | | 05 | 招聘與發展 | 46 | | | 薪酬與福利 | ...

证券代码：688366 证券简称：昊海生科 公告编号：2025-018 上海昊海生物科技股份有限公司 关于变更注册资本并修订公司章程的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海昊海生物科技股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召开第五届董事会第三十一次会议，审议通过了《关于变更公司注册资本并修 订公司章程的议案》等议案，现将相关事项公告如下： 一、变更注册资本 公司于 2024 年 5 月 29 日召开的 2023 年度股东周年大会、2024 年第一次 A 股类别股东大会及 2024 年第一次 H 股类别股东大会审议通过了《关于授予董事 会回购 H 股的一般性授权的议案》，并于 2024 年 6 月 3 日召开第五届董事会第 二十四次会议，审议通过了《关于上海昊海生物科技股份有限公司回购 H 股股 份的议案》。根据前述一般性授权和决议，公司于 2024 年 6 月 27 日至 2024 年 12 月 4 日期间合计回购 H 股股份 2,296,200 股，并分别于 2024 年 ...

Financial Performance - The company's operating revenue for 2024 reached RMB 2,697,657,908.35, representing a 1.64% increase compared to RMB 2,654,039,068.79 in 2023[22]. - The net profit attributable to shareholders for 2024 was RMB 420,446,906.16, a slight increase of 1.04% from RMB 416,121,340.71 in 2023[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 379,096,331.64, showing a decrease of 1.12% compared to RMB 383,406,434.26 in 2023[22]. - The net cash flow from operating activities for 2024 was RMB 648,571,330.09, an increase of 2.23% from RMB 634,449,395.83 in 2023[22]. - As of the end of 2024, the net assets attributable to shareholders were RMB 5,575,258,634.87, a decrease of 1.32% from RMB 5,650,064,203.23 at the end of 2023[22]. - The total assets at the end of 2024 amounted to RMB 7,121,392,176.35, reflecting a slight increase of 0.22% from RMB 7,105,496,951.15 at the end of 2023[22]. - The company's gross profit margin for 2024 was 69.89%, slightly down from 70.46% in the previous year[32]. - The company achieved a revenue of 2,529.85 billion yuan in the pharmaceutical manufacturing industry in 2024, ranking 16th among 41 industrial categories, with a profit total of 342.07 billion yuan, a year-on-year decrease of 1.1%[80]. Dividend Distribution - The proposed cash dividend for the 2024 fiscal year is CNY 6.00 per 10 shares, totaling CNY 138,023,048.40 (including tax) based on a total share capital of 233,193,695 shares, after deducting 3,155,281 shares held in the repurchase account[8]. - The total cash dividend for 2024, including interim distributions, amounts to CNY 230,925,296.80, representing 54.92% of the net profit attributable to shareholders of the listed company[8]. - The company plans to submit the profit distribution proposal to the 2024 annual general meeting of shareholders for approval[8]. Research and Development - Research and development expenses for 2024 amounted to CNY 238.93 million, an increase of CNY 18.83 million, or approximately 8.56% year-on-year, representing 8.86% of total revenue[33]. - The company has a dedicated R&D team of 350 members, accounting for 16.23% of total employees, including 25 PhD holders and 107 master's degree holders[161]. - The company is actively pursuing clinical trials for various new products, including pain-reducing cross-linked sodium hyaluronate gel, which is currently in clinical testing[104]. - The company has established a comprehensive R&D management system and innovation incentive mechanism to enhance its technological capabilities[165]. - The company has filed for 56 new patents during the reporting period, with 59 patents granted, bringing the total to 468[98]. Product Development and Innovation - The company launched the world's first organic cross-linked hyaluronic acid product "Hai Mei Yue Bai" in July 2024, and received approval for its ophthalmic sodium hyaluronate eye drops in March 2024[33]. - The company is focusing on the integration of technologies such as stem cells, tissue engineering, and 3D printing to expand the application of biomedical materials in medical fields[86]. - The company is currently developing new products, including hydrophilic continuous vision intraocular lenses and collagen solutions for skin care, with R&D investments starting in 2024[178]. - The company is advancing various projects in the ophthalmology field, with multiple artificial lens products completing clinical trials and receiving regulatory certifications in early 2025[162]. - The company has developed a patented technology for medical chitosan, which has won multiple national awards, highlighting its innovation capabilities[107]. Market Position and Strategy - The company is committed to maintaining compliance with regulatory standards set by the National Medical Products Administration (NMPA)[16]. - Future outlook includes market expansion strategies and potential mergers and acquisitions to enhance competitive positioning[16]. - The company aims to leverage its research capabilities to drive innovation in medical devices and biopharmaceuticals[16]. - The company is focusing on four major therapeutic areas: medical aesthetics, ophthalmology, orthopedics, and adhesion prevention, which are expected to drive future growth[145]. - The company is actively engaged in the development of new products and technologies, focusing on the biomedical sector[192]. Compliance and Governance - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[11]. - The company has not violated decision-making procedures for external guarantees[11]. - The company has received a standard unqualified audit report from Ernst & Young Hua Ming[7]. - The board of directors and supervisory board members confirm the authenticity, accuracy, and completeness of the annual report[4]. - The governance structure is designed to ensure clear responsibilities and effective decision-making processes within the company[197]. Risks and Challenges - The company faces risks related to technological advancements in the biomedical materials field, which could impact its market competitiveness if it fails to adapt[115]. - The company is exposed to operational risks, including potential product quality issues that could lead to recalls and reputational damage[116]. - The company is affected by industry risks due to ongoing reforms in the pharmaceutical and medical device sectors, which may increase compliance costs and reduce product demand[117]. - The company's growth is partially dependent on the overall growth of the biopharmaceutical industry in China, which could slow down due to various factors[118]. - The company has pursued international expansion through acquisitions, which may be impacted by changes in foreign regulations or geopolitical tensions[118].

2024 年 報 目 錄 | 公司資料 | 2 | | --- | --- | | 財務摘要 | 4 | | 主席致辭 | 5 | | 管理層討論與分析 | 7 | | 董事會報告 | 25 | | 企業管治報告 | 53 | | 董事、監事及高級管理人員簡介 | 73 | | 獨立核數師報告 | 80 | | 綜合損益及其他綜合收益表 | 86 | | 綜合財務狀況表 | 88 | | 綜合權益變動表 | 90 | | 綜合現金流量表 | 92 | | 財務報表附註 | 95 | | 釋義 | 195 | | 技術詞彙 | 199 | 上海昊海生物科技股份有限公司 2 公司資料 第五屆董事會 執行董事： 侯永泰博士 （主席） 吳劍英先生 （總經理） 陳奕奕女士 唐敏捷先生 （財務總監） 非執行董事： 游捷女士 黃明先生 獨立非執行董事： 沈紅波先生 姜志宏先生 蘇治先生 楊玉社先生 趙磊先生 第五屆監事會 劉遠中先生 （主席） 楊青女士 唐躍軍先生 魏長征先生 宋霄女士 授權代表 黃明先生 趙明璟先生 聯席公司秘書 田敏女士 趙明璟先生 （香港公司治理公會資深會員） 審計委員會 沈紅波先生（ 主席） 游捷女 ...

证券代码：688366 证券简称：昊海生科 公告编号：2025-017 上海昊海生物科技股份有限公司 第五届监事会第二十一次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 上海昊海生物科技股份有限公司（以下简称"公司"）第五届监事会第二十 一次会议（以下简称"本次会议"）于2025年4月25日15:00时以现场结合通讯方 式召开，本次会议通知已于2025年4月11日以书面方式送达公司全体监事。本次 会议由监事会主席刘远中先生主持，会议应参加监事5人，实际参加监事5人。本 次会议的召集、召开符合《中华人民共和国公司法》等法律、法规和《上海昊海 生物科技股份有限公司章程》（以下简称"《公司章程》"）的有关规定。 二、监事会会议审议情况 经与会监事审议，做出以下决议： 1.审议通过《关于公司2025年第一季度报告的议案》 监事会认为：公司2025年第一季度报告的编制和审议程序符合法律、法规、 《公司章程》和公司内部管理制度的各项规定； 公司2025年第一季度报告的内容与格式符合上海证券交易所 ...